Accuracy of MRI in Prediction of Pathologic Complete Remission in Breast Cancer After Preoperative Therapy: A Meta-Analysis
- 1 July 2010
- journal article
- research article
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 195 (1), 260-268
- https://doi.org/10.2214/ajr.09.3908
Abstract
OBJECTIVE. Prediction of pathologic complete remission in breast cancer after preoperative therapy presents difficulties. We performed a meta-analysis to determine the ability of MRI to predict pathologic complete remission in patients with breast cancer after preoperative therapy.MATERIALS AND METHODS. Medical subject heading terms (“MRI” and “Breast Neoplasm”) and key words (“neoadjuvant” or “primary systemic” or “preoperative” or “presurgery”) were used for a literature search in the MEDLINE database. A meta-analysis of pooled data from eligible studies was performed to estimate the accuracy of MRI in predicting pathologic complete remission after preoperative therapy in patients with breast cancer.RESULTS. Twenty-five studies were included in this meta-analysis. Pooled weighted estimates of sensitivity and specificity were 0.63 (range, 0.56–0.70) and 0.91 (range, 90.89–0.92), respectively. Heterogeneity between studies was highly influenced by the pathologic complete remission rate, with a regression ...This publication has 55 references indexed in Scilit:
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Journal of Clinical Oncology, 2008
- Meta-Analysis of MR Imaging in the Diagnosis of Breast LesionsRadiology, 2008
- Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006Annals Of Oncology, 2007
- Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapyAnnals of Oncology, 2007
- Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapyCancer, 2007
- HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combinationBMC Cancer, 2007
- Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancerJournal of Clinical Oncology, 2005
- Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-AnalysisJNCI Journal of the National Cancer Institute, 2005
- The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2003
- Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18JNCI Monographs, 2001